) --




) hit a new 52-week high Monday as it traded at $28 compared with its previous 52-Week high of $27.97. Targacept is changing hands at $27.92 with 14,853 shares traded as of 9:37 a.m. ET. Average volume has been 103,500 shares over the past 30 days.

Targacept has a market cap of $765.6 million and is part of the

health care

sector and


industry. Shares are up 1.1% year to date as of the close of trading on Friday.

Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of novel Neuronal Nicotinic Receptors (NNR) Therapeutics for the treatment of diseases and disorders of the central nervous system. The company has a P/E ratio of 74.2, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 22.6.

TheStreet Ratings rates Targacept as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. You can view the full

Targacept Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center